Unicycive Therapeutics (NASDAQ:UNCY) Earns “Buy” Rating from HC Wainwright

Unicycive Therapeutics (NASDAQ:UNCY)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $4.00 target price on the stock.

Separately, Benchmark reaffirmed a “speculative buy” rating and set a $3.00 price target on shares of Unicycive Therapeutics in a research report on Friday, November 22nd. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $5.50.

Unicycive Therapeutics Stock Performance

Shares of NASDAQ:UNCY opened at $0.58 on Wednesday. Unicycive Therapeutics has a 52 week low of $0.20 and a 52 week high of $1.82. The company has a market capitalization of $60.20 million, a PE ratio of -0.60 and a beta of 2.30. The company has a 50 day moving average price of $0.69 and a two-hundred day moving average price of $0.51.

Institutional Trading of Unicycive Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of UNCY. XTX Topco Ltd bought a new stake in Unicycive Therapeutics during the third quarter worth $29,000. Virtu Financial LLC lifted its position in shares of Unicycive Therapeutics by 566.8% in the third quarter. Virtu Financial LLC now owns 73,975 shares of the company’s stock valued at $30,000 after buying an additional 62,881 shares during the last quarter. Bleakley Financial Group LLC acquired a new position in shares of Unicycive Therapeutics during the 3rd quarter worth approximately $33,000. Acuta Capital Partners LLC bought a new stake in Unicycive Therapeutics in the 3rd quarter valued at $807,000. Finally, Walleye Capital LLC bought a new position in Unicycive Therapeutics during the third quarter worth $2,040,000. Institutional investors and hedge funds own 40.42% of the company’s stock.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.